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Background: The purpose of the current study is to analyze the existing data comparing neoadjuvant
chemotherapy with primary debulking surgery (PDS) in patients with advanced ovarian carcinoma.
Methods: Patients with stage IIIC and IV ovarian cancer were identified from articles in Medline, PubMed, Cochrane
Library, and EMBASE database (1989 to February 2013). Two authors independently extracted the data. To assess
the risk of bias of included literatures, Cochrane Collaboration’s risk of bias tool was used. Meta-analysis on
literatures was conducted by using RevMan 5.2 software.
Results: Two high-quality randomized controlled trials (RCTs) met the inclusion criteria. These multicenter trials
randomized 1,220 women with stage IIIc/IV ovarian cancer to NACT or PDS followed by chemotherapy. There were
no significant differences between the study groups with regard to overall survival (OS) (1,120 women; HR 0.98;
95% CI 0.85 to 1.14) or progression-free survival (PFS) (1,120 women; HR 1.03; 95% CI 0.91 to 1.16).
Conclusion: There was no statistical difference in median OS and PFS between the two treatment groups. With
regard to selecting who will benefit from NACT, treatment should be tailored to the patient and should take into
account respectability, age, histology, stage, and performance status.
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Introduction
An estimated 22,280 new cases of ovarian cancer are
expected in the US in 2012 [1]. Ovarian cancer causes
more deaths than any other cancer of the female repro-
ductive system [1]. In most patients with ovarian carcin-
oma, the disease is diagnosed at an advanced stage and
they usually have a very poor prognosis [2].
Primary surgical treatment of ovarian cancer has ad-
vantages in terms of diagnosis, staging, and tumor
debulking [3,4]. The value of debulking surgery is well
established in FIGO stage III epithelial ovarian cancer
[5]. Most women will have widespread disease, therefore
surgery alone does not cure the disease. Neoadjuvant
chemotherapy (NACT) prior to surgical debulking pro-
poses to increase the proportion of patients who may be* Correspondence: mdylx@163.com
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reproduction in any medium, provided the oroptimally cytoreduced, while decreasing surgical mor-
bidity and mortality [6].
Several retrospective studies have shown that there was
no difference in overall survival (OS) or progression-free
survival (PFS) for patients with advanced ovarian cancer
treated with neoadjuvant chemotherapy compared with
primary debulking surgery (PDS) [7-11]. However, the re-
sult of a meta-analysis of Bristow and Chi [12] involving
835 patients suggested that NACT, compared with PDS,
was associated with a worse OS and it was suggested that
the definitive operative intervention should be undertaken
as early in the treatment program as possible. But a more
recent meta-analysis [13] of multiply central randomized
trials concluded that survival was similar in patients
treated with NACT followed by interval debulking surgery
compared to primary debulking followed by chemotherapy
and criticized the meta-analysis of Bristow and Chi [12].
Since randomized controlled trials (RCTs) are the ‘gold
standard’ of evidence-based medical research, we hopeal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the benefits and risks are of using NACT for women
with advanced ovarian cancer, compared with the
standard treatment of PDS [13,14]. The purpose of the
current study is to analyze the existing data comparing
NACT with PDS in patients with advanced ovarian car-
cinoma which included more RCTs.
Methods
Literature research
We undertook computerized literature searches of
MEDLINE, PubMed, Cochrane Library, and EMBASE
databases, from their inception to February 2013.
Search terms were ‘ovarian carcinoma’, ‘ovarian cancer’,
‘neoadjuvant chemotherapy’, and ‘primary surgery’.
These terms were used in different combinations with
each other. Appropriate references cited by the re-
trieved studies were also identified.
Study selection
Publications were selected for initial review if the re-
search subjects were patients with International Feder-
ation of Gynecology and Obstetrics (FIGO) stage III and
IV ovarian cancer who underwent NACT and PDS. In
order to fully exclude the possibility of selection bias,
only RCTs of NACT versus PDS were permitted. Dupli-
cate publications or data were carefully reviewed by two
of the authors and the larger (primary decision) or the
most recent publication was included.
Data on trial size, patient characteristics (age, sex, AF
duration, left ventricular size, left ventricular ejection frac-
tion, and so on), procedure duration, and patient number
of sinus rhythm maintenance without anti-arrhythmic
drugs were extracted. Included studies were reviewed basedFigure 1 Process of study selection.on randomization, allocation concealment, blinding, loss of
follow-ups, and ITT. The truths of the studies were divided
into three grades according to Cochrane system evaluation
handbook: Grade A, cases met all evaluated standards and
had correct methodology, which had low risk of bias;
Grade B, cases did not describe one or several standards,
which had moderate risk of bias; Grade C, cases had one
or several standards incorrect, which had high risk of bias.
Data extraction
All the work of the literature search was independently
reviewed by two authors to identify relevant trials that
met the inclusion criteria and checked by an independ-
ent reviewer. Disparities were resolved by discussion.
The following data were extracted from each study: (1)
publication and trial characteristics, including the first
author’s name, publication year, study period, center,
study design, and sample size; (2) clinical data, including
patient data (gender, age, quality of life) and tumor data
(histological characteristics and grade classifications); (3)
data of outcome, including value of OS and PFS. All data
were centrally reanalyzed and checked for inconsisten-
cies. In this article, the primary endpoint was OS.
Secondary endpoints were PFS. OS was defined as the
time from distribution until death from any cause or to
the last follow-up that was used as a date of censoring.
PFS was defined as the time from distribution to relapse
or death from any cause, whichever came first. Data for
patients alive without progression were censored on the
date of last follow-up.
Statistical analysis
Meta-analyses were carried out by one author using
RevMan5.2. For survival outcomes (OS and PFS), the log
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Figure 2 Overall survival outcome.
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analysis using the Generic Inverse Variance facility of
RevMan5.2. As a data analysis method, a fixed effect
model was applied when the homogeneity between




The search process of the study is shown in Figure 1. A
total of 226 publications were identified after initial search.
The titles and abstracts of these articles were examined to
exclude irrelevant trials. We also examined the reference
lists of all relevant letters, editorials, and review articles.
As a result, two articles possibly met the selection criteria
(Peter G Rose et al., 2004; IgnaceVergote et al., 2010). Sub-
sequently, the full text of these studies was examined
thoroughly.
Overall survival
There was no significant difference in OS between the
NACT and PDS groups (1,120 women; HR 0.98; 95% CI
0.85 to 1.14; Figure 2).
Progression-free survival
The existing data showed no significant difference in
PFS between the NACT and PDS groups (670 women;
HR 1.01; 95% CI 0.87 to 1.17; Figure 3).Study or Subgroup
Peter G. Rose 2004
Ignace Vergote 2010
Total (95% CI)
Heterogeneity: Chi² = 0.20, df = 1 (P = 0.66); I² = 0%
















Figure 3 Progress-free survival outcome.Conclusion
There was no statistical difference in median OS and
PFS between the two treatment groups. With regard to
selecting who will benefit from NACT, treatment should
be tailored to the patient and should take into account
respectability, age, histology, stage, and performance
status.
Discussion
The clinical basis of aggressive cytoreductive surgery in
the initial management of ovarian cancer is the signifi-
cantly improved survival gained by those patients in
whom optimal cytoreductive surgery was accomplished
[14]. The presence of residual disease after surgery is one
of the most adverse prognostic factors for survival. There-
fore, although the definition of optimal cytoreduction has
been modified over the last two decades, it is generally
agreed that every attempt should be made to surgically
resect as much disease as safely possible [15]. There are
many hypothesized advantages to NACT in women who
have advanced ovarian cancer that likely cannot be op-
timally cytoreduced. Chemotherapy can resolve pleural
effusions and ascites and improve the patient’s perform-
ance status prior to surgery [16,17]. There have been re-
ports of subjective improvements in the sense of wellbeing
and quality of life [18,19]. It can decrease tumor volume
and increase respectability. Thus, patients may have less
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pital stay [4,14,19]. These issues are particularly important
for patients with medical co-morbidities and a low
probability of cure.
Primary cytoreductive surgery is still the gold standard
in the treatment of ovarian carcinoma [20]. NACT for ad-
vanced unresectable ovarian carcinoma led to the selec-
tion of a group of patients sensitive to chemotherapy, in
whom secondary cytoreductive surgery can be achieved in
a less aggressive manner. Also NACT prevents mutilating
surgery in patient with a very poor prognosis either
because of progressive disease or because of primary
chemoresistance. These findings must be confirmed by a
larger prospective study [21].
There are several limitations to this current study that
must be considered in interpreting the data. This is a
retrospective study, the limitations imposed by these
attributes have to be borne in mind when interpreting or
using the findings [22]. A standardized protocol to
monitor chemotherapy response was not used in these
patients thus potentially introducing lead-time bias, nor
was our study designed to control for various second
and further-line treatment regimens, which may have
the ultimate impact on OS [23].
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